N-(3-acetoxy-2-naphthoyl)-4-aminophenyl guanidine | 345237-12-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: N-(3-acetoxy-2-naphthoyl)-4-aminophenyl guanidine
• 英文别名: [3-[[4-(Diaminomethylideneamino)phenyl]carbamoyl]naphthalen-2-yl] acetate
• CAS: 345237-12-9
• 化学式: C₂₀H₁₈N₄O₃
• 分子量: 362.388
• InChiKey: VYAATWOISARDAT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.05
• 拓扑面积：
  120
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(3-acetoxy-2-naphthoyl)-4-aminophenyl guanidine 在 ammonium hydroxide 作用下， 以 四氢呋喃 为溶剂， 生成 N-[4-(diaminomethylideneamino)phenyl]-3-hydroxynaphthalene-2-carboxamide
  参考文献：
  名称：

  4-Aminoarylguanidine and 4-aminobenzamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors

  摘要：

  The structure-based design of potent and selective urokinase-type plasminogen activator (uPA) inhibitors with 4-aminoarylamidine or 4-aminoarylguanidine S1 binding groups, is described. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00312-8
• 作为产物：
  描述：

  3-乙酰基氧基-2-萘甲酸 在 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 N,N-二甲基乙酰胺 、 乙酸乙酯 为溶剂， 反应 18.0h， 生成 N-(3-acetoxy-2-naphthoyl)-4-aminophenyl guanidine
  参考文献：
  名称：

  4-Aminoarylguanidine and 4-aminobenzamidine derivatives as potent and selective urokinase-type plasminogen activator inhibitors

  摘要：

  The structure-based design of potent and selective urokinase-type plasminogen activator (uPA) inhibitors with 4-aminoarylamidine or 4-aminoarylguanidine S1 binding groups, is described. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00312-8

文献信息

• Salicylamides as serine protease inhibitors
  申请人：——

  公开号：US20020052343A1

  公开（公告）日：2002-05-02

  The present invention provides novel compounds of Formula I: 1 its prodrug forms, or pharmaceutically acceptable salts thereof. The compounds of this invention are inhibitors of serine proteases, Urokinase (uPA), Factor Xa (FXa), and/or Factor VIIa (FVIIa), and have utility as anti cancer agents and/or as anticoagulants for the treatment or prevention of thromboembolic disorders in mammals. The present invention also provides a process for the selective acylation of an amino group.

  本发明提供了Formula I的新化合物、其前药形式或其药用可接受的盐。本发明的化合物是丝氨酸蛋白酶、尿激酶（uPA）、凝血因子Xa（FXa）和/或凝血因子VIIa（FVIIa）的抑制剂，并且具有作为抗癌剂和/或抗凝剂在哺乳动物中治疗或预防血栓栓塞性疾病的用途。本发明还提供了一种选择性酰化氨基团的方法。
• Salicylamides as serine protease and factor xa inhibitors
  申请人：——

  公开号：US20030232789A1

  公开（公告）日：2003-12-18

  The present invention provides novel compounds of Formula (I), its prodrug forms, or pharmaceutically acceptable salts thereof. The compounds of this invention are inhibitors of serine proteases, Urokinase (uPA), Factor Xa (FXa), and/or Factor VIIa (FVIIa), and have utility as anti cancer agents and/or as anticoagulants for the treatment or prevention of thromboembolic disorders in mammals. The present invention also provides a process for the selective acylation of an amino group. 1

  本发明提供一种新的化合物Formula (I)，其前药形式或药学上可接受的盐。本发明的化合物是丝氨酸蛋白酶、尿激酶（uPA）、因子Xa（FXa）和/或因子VIIa（FVIIa）的抑制剂，并具有作为抗癌剂和/或抗凝剂在哺乳动物中治疗或预防血栓栓塞性疾病的用途。本发明还提供一种选择性酰化氨基的过程。
• SALICYLAMIDES AS SERINE PROTEASE AND FACTOR XA INHIBITORS
  申请人：AXYS PHARMACEUTICALS, INC.

  公开号：EP1242366A1

  公开（公告）日：2002-09-25
• [EN] SALICYLAMIDES AS SERINE PROTEASE AND FACTOR XA INHIBITORS<br/>[FR] SALICYLAMIDES UTILES EN TANT QU'INHIBITEURS DES SERINES PROTEASES
  申请人：AXYS PHARM INC

  公开号：WO2001044172A1

  公开（公告）日：2001-06-21

  The present invention provides novel compounds of Formula (I), its prodrug forms, or pharmaceutically acceptable salts thereof. The compounds of this invention are inhibitors of serine proteases, Urokinase (uPA), Factor Xa (FXa), and/or Factor VIIa (FVIIa), and have utility as anti cancer agents and/or as anticoagulants for the treatment or prevention of thromboembolic disorders in mammals. The present invention also provides a process for the selective acylation of an amino group.